医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Recent Settlement in Promega/Genovis Case Maintains Continued Offering of Promega IdeS/IdeZ Proteases

2016年06月30日 PM03:00
このエントリーをはてなブックマークに追加


 

MADISON, Wis.

A recent settlement between Promega Corporation and Genovis AB maintains full freedom for the continued offering of Promega’s IdeS and IdeZ Proteases for markets worldwide. In November of 2014, Genovis and Hansa Medical AB filed a patent infringement suit in the U.S. While the details of the settlement are confidential, it allows for continued manufacture, sale and support of IdeS and IdeZ by Promega.

These products are used by scientists worldwide for a host of applications including early stage characterization of potential therapeutic antibodies that may someday be important for treating different diseases. The settlement allows that work to continue without interruption.

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 3,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160629006456/en/

CONTACT

Promega Corporation
Penny Patterson
Sr. Director,
Communications
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • FDA Grants Priority Review for Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
  • TL PLASTIC SURGERY in South Korea, the Best Choice for Your Satisfying Breast Augmentation Surgery
  • Ascendia Pharmaceuticals宣布其治疗急性冠脉综合征的ASD-002项目获颁一项新专利
  • 年次世界患者安全・科学・技術サミットで初めて米国外向けにHDライブストリーミングを実施へ
  • Accelsiors CRO Expands Global Footprint